Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.

Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP.

Vaccine. 2014 Feb 12;32(8):1019-28. doi: 10.1016/j.vaccine.2013.10.039. Epub 2013 Dec 25.

PMID:
24373307
2.

Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.

Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP; Anthrax Vaccine Research Program Working Group.

JAMA. 2008 Oct 1;300(13):1532-43. doi: 10.1001/jama.300.13.1532. Erratum in: JAMA. 2008 Nov 19;300(19):2252.

PMID:
18827210
3.

Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Pondo T, Rose CE Jr, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker S, Jacobson RM, Poland GA, McNeil MM.

Vaccine. 2014 Jun 12;32(28):3548-54. doi: 10.1016/j.vaccine.2014.04.025. Epub 2014 Apr 24.

PMID:
24768633
4.

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM.

Vaccine. 2002 Jan 31;20(9-10):1412-20.

PMID:
11818160
5.

Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans.

Schiffer JM, Chen L, Dalton S, Niemuth NA, Sabourin CL, Quinn CP.

Vaccine. 2015 Jul 17;33(31):3709-16. doi: 10.1016/j.vaccine.2015.05.091. Epub 2015 Jun 10.

6.

A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N; AVRP Laboratory Working Group.

Clin Vaccine Immunol. 2012 Nov;19(11):1730-45. doi: 10.1128/CVI.00324-12. Epub 2012 Aug 29.

7.

Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

Pittman PR, Fisher D, Quinn X, Schmader T, Barrera-Oro JG.

Vaccine. 2013 Oct 17;31(44):5009-14. doi: 10.1016/j.vaccine.2013.08.086. Epub 2013 Sep 8.

PMID:
24026013
8.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9. Epub 2006 Jun 5.

PMID:
16797805
9.

Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.

Pittman PR, Cavicchia MA, Kingsbury JL, Johnson NA, Barrera-Oro JG, Schmader T, Korman L, Quinn X, Ranadive M.

Vaccine. 2014 Sep 3;32(39):5131-9. doi: 10.1016/j.vaccine.2014.03.076. Epub 2014 May 14.

PMID:
24837771
10.

Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

Hopkins RJ, Daczkowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C, Sari S, Rudge TL, Bernton E.

Vaccine. 2013 Jun 26;31(30):3051-8. doi: 10.1016/j.vaccine.2013.04.063. Epub 2013 May 10.

11.

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Parker SD, Babcock J, Keitel W, Poland GA, Keyserling HL, El Sahly H, Jacobson RM, Marano N, Plikaytis BD, Wright JG.

Clin Vaccine Immunol. 2016 Apr 4;23(4):326-38. doi: 10.1128/CVI.00696-15. Print 2016 Apr.

PMID:
26865594
12.

Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.

Semenova VA, Schiffer J, Steward-Clark E, Soroka S, Schmidt DS, Brawner MM, Lyde F, Thompson R, Brown N, Foster L, Fox S, Patel N, Freeman AE, Quinn CP.

J Immunol Methods. 2012 Feb 28;376(1-2):97-107. doi: 10.1016/j.jim.2011.12.002. Epub 2011 Dec 17.

PMID:
22197974
13.

Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN.

Vaccine. 2008 Feb 13;26(7):869-73. doi: 10.1016/j.vaccine.2007.11.085. Epub 2007 Dec 26.

14.

Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.

Zhang Y, Martin SW, Rose CE Jr, Biagini RE, Franzke LH, Smith JP, Sammons DL, Robertson SA, McNeil MM.

Pharmacoepidemiol Drug Saf. 2008 Nov;17(11):1060-7. doi: 10.1002/pds.1657.

PMID:
18781705
15.

Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.

Bernstein DI, Jackson L, Patel SM, El Sahly HM, Spearman P, Rouphael N, Rudge TL Jr, Hill H, Goll JB.

Vaccine. 2014 Oct 29;32(47):6284-93. doi: 10.1016/j.vaccine.2014.08.076. Epub 2014 Sep 17.

16.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

17.

Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.

Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT Jr, Friedlander AM, Sjogren MH.

Vaccine. 2002 May 15;20(16):2107-15.

PMID:
11972980
18.

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.

Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.

Hum Vaccin. 2007 Sep-Oct;3(5):205-11. Epub 2007 May 18.

PMID:
17881903
19.

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.

Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Miller J, Alpar HO, Baillie LW, Williamson ED.

Infect Immun. 2002 Apr;70(4):2022-8.

20.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3. Epub 2007 May 13.

PMID:
17375001
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk